Back to today’s briefing

Story perspectives

FDA's AI Chatbot Faces Trust Issues Amid Drug Review Push

8/3/2025

50 7

Summary

Story summary

The FDA's AI chatbot, Elsa, designed to streamline drug reviews, is grappling with serious hurdles like technical glitches and trust concerns. Staff worry about transparency and data security, raising skepticism. However, if integrity and oversight are prioritized, there’s hope for effective collaboration. Critics stress the urgent need for dependable technology in safeguarding public health.

1 of 1

Story summary

The FDA's AI chatbot, Elsa, designed to streamline drug reviews, is grappling with serious hurdles like technical glitches and trust concerns. Staff worry about transparency and data security, raising skepticism. However, if integrity and oversight are prioritized, there’s hope for effective collaboration. Critics stress the urgent need for dependable technology in safeguarding public health.